New Alzheimer’s Treatment
Galectin-3 is a glue-like protein, which gets released from the tissue when inflammation sets in. This is true for the brain with Alzheimer’s disease, but also in major organs that are chronically inflamed like the liver, the heart, lungs and kidneys. Here the discussion centers around Alzheimer’s disease because the California company TrueBinding has developed a specific monoclonal antibody medication to treat Alzheimer’s. It will be cheaper than Aduhelm, a similar drug. The experimental drug is termed TB006, but will eventually get a proper pharmacological name when phase 3 of the clinical trial is complete. This will take another 2 to 3 years. TB006 produced a 63% reduction in worsening on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at three months compared to placebo.?